Protective effect of single‐dose adjuvanted pandemic influenza vaccine in children

201053 citationsJournal Articlebronze Open Access

Authors

Paul Van Buynder · The University of Western Australia

Jessie Kaur DHALIWAL · Government of New Brunswick

J.L. Van Buynder · Government of New Brunswick

Cyril Couturier · Government of New Brunswick

M. Minville‐LeBlanc · Government of New Brunswick

Richard Garceau · Dr. Georges-L.-Dumont University Hospital Centre

Francios‐William Tremblay

Abstract

A single 0.25-ml dose of the GSK adjuvanted vaccine (Arepanrix) protects children against laboratory-confirmed pandemic influenza potentially avoiding any increased reactogenicity associated with second doses. Adjuvanted vaccines offer hope for improved seasonal vaccines in the future.

Topics & Keywords

Influenza Virus Research Studies Respiratory viral infections research SARS-CoV-2 and COVID-19 Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Influenza and Other Respiratory Viruses

Volume 4, Issue 4, pp. 171-178

DOI: 10.1111/j.1750-2659.2010.00146.x

Field-Weighted Citation Impact: 6.45